

# Ottavia Bernocchi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5667913/publications.pdf>

Version: 2024-02-01

10  
papers

239  
citations

1478505

6  
h-index

1372567

10  
g-index

11  
all docs

11  
docs citations

11  
times ranked

455  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature. <i>Pharmaceuticals</i> , 2021, 14, 159.	3.8	7
2	Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort Study. <i>Cancers</i> , 2021, 13, 1324.	3.7	8
3	Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study. <i>International Journal of Infectious Diseases</i> , 2021, 104, 433-440.	3.3	47
4	Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET). <i>Clinical Cancer Research</i> , 2021, 27, 3443-3455.	7.0	4
5	Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021, 149, 134-152.	2.8	41
6	Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial. <i>Frontiers in Oncology</i> , 2021, 11, 686776.	2.8	13
7	Early Changes of the Standardized Uptake Values (SUVmax) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. <i>Cancers</i> , 2020, 12, 3314.	3.7	5
8	Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 421-431.	2.5	9
9	Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study. <i>Oncotarget</i> , 2020, 11, 2172-2181.	1.8	5
10	Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer. <i>Cells</i> , 2019, 8, 321.	4.1	100